首页 > 最新文献

Chinese Medicine最新文献

英文 中文
Protective effect of Huashi Baidu formula against AKI and active ingredients that target SphK1 and PAI-1. 华氏百户方对 AKI 的保护作用以及针对 SphK1 和 PAI-1 的有效成分。
IF 5.3 3区 医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-11-01 DOI: 10.1186/s13020-024-01024-7
Yute Zhong, Xia Du, Ping Wang, Weijie Li, Cong Xia, Dan Wu, Hong Jiang, Haiyu Xu, Luqi Huang
<p><strong>Background: </strong>Huashi Baidu Formula (HBF) is a clinical formula known for its efficacy against coronavirus disease 2019 (COVID-19). HBF may reduce the number of patients with abnormal serum creatinine while improving respiratory symptoms, suggesting that this formula may have potential for treating acute kidney injury (AKI). However, the protective effect of HBF on AKI has not been definitively confirmed, and the mechanism remains unclear. Therefore, the present study explored the renoprotective effects and molecular mechanisms of HBF and screened for its active ingredients to identify new potential applications of renoprotection by HBF.</p><p><strong>Methods: </strong>The present study first assessed the protective effects of HBF on AKI in a DOX-induced mouse model. Then, RNA-seq and bioinformatics analyses were used to explore the related pathological processes and potential molecular mechanisms, which were subsequently validated using qRT-PCR and Western blotting. Furthermore, candidate compounds with potential binding affinity to two pivotal targets, sphingosine kinase 1 (SphK1) and plasminogen activator inhibitor-1 (PAI-1), were screened from the 29 constituents present in the blood using Microscale Thermophoresis (MST). Finally, to identify the active ingredients, the candidate components were re-screened using the SphK1 kinase activity detection system or the uPA/PAI-1 substrate colorimetric assay system.</p><p><strong>Results: </strong>In the DOX-induced AKI mouse model, therapeutic administration of HBF significantly reduced the levels of CRE, BUN, TNF-α, IL-1β, IL-6, and UA in plasma and the levels of MDA, T-CHO, and TG in kidney tissue. Additionally, the levels of TP and Alb in plasma and SOD and CAT in the kidney tissue were significantly increased. Histopathological assessment revealed that HBF reduced tubular vacuolation, renal interstitial inflammatory cell infiltration, tubular atrophy, and positive staining of renal interstitial collagen. RNA-seq and bioinformatics analyses showed that oxidative stress, the immune-inflammatory response, and extracellular matrix (ECM) formation could be the pathological processes that HBF targets to exerts its renoprotective effects. Furthermore, HBF regulated the APJ/SPHK1/NF-κB and APJ/PAI-1/TGFβ signaling axes and reduced the phosphorylation levels of NF-κB p65 and SMAD2 and the expression of cytokines and the ECM downstream of the axis. Finally, six SphK1 inhibitors (paeoniflorin, astragalin, emodin, glycyrrhisoflavone, quercetin, and liquiritigenin) and three PAI-1 inhibitors (glycyrrhisoflavone, licochalcone B, and isoliquiritigenin) were identified as potentially active ingredients in HBF.</p><p><strong>Conclusion: </strong>In brief, our investigation underscores the renoprotective effect of HBF in a DOX-induced AKI model mice, elucidating its mechanisms through distinct pathological processes and identifying key bioactive compounds. These findings offer new insights for br
背景:华氏百户方(HBF)是一种临床配方,因其对冠状病毒病 2019(COVID-19)的疗效而闻名。HBF 可减少血清肌酐异常患者的数量,同时改善呼吸道症状,这表明该配方可能具有治疗急性肾损伤(AKI)的潜力。然而,HBF 对 AKI 的保护作用尚未得到明确证实,其机制也仍不清楚。因此,本研究探讨了 HBF 的肾脏保护作用和分子机制,并筛选了其活性成分,以确定 HBF 肾脏保护的新潜在应用:本研究首先评估了HBF在DOX诱导的小鼠模型中对AKI的保护作用。然后,使用 RNA-seq 和生物信息学分析来探索相关的病理过程和潜在的分子机制,并随后使用 qRT-PCR 和 Western 印迹进行验证。此外,利用微尺度热电泳技术(MST)从血液中的 29 种成分中筛选出了与鞘氨醇激酶 1(SphK1)和纤溶酶原激活物抑制剂-1(PAI-1)这两个关键靶点具有潜在结合亲和力的候选化合物。最后,为了确定活性成分,使用 SphK1 激酶活性检测系统或 uPA/PAI-1 底物比色检测系统对候选成分进行了再筛选:结果:在 DOX 诱导的 AKI 小鼠模型中,治疗性服用 HBF 能显著降低血浆中 CRE、BUN、TNF-α、IL-1β、IL-6 和 UA 的水平,以及肾组织中 MDA、T-CHO 和 TG 的水平。此外,血浆中 TP 和 Alb 的水平以及肾组织中 SOD 和 CAT 的水平也明显升高。组织病理学评估显示,HBF 减少了肾小管空泡化、肾间质炎症细胞浸润、肾小管萎缩和肾间质胶原的阳性染色。RNA-seq和生物信息学分析表明,氧化应激、免疫炎症反应和细胞外基质(ECM)的形成可能是HBF发挥肾脏保护作用所针对的病理过程。此外,HBF还能调节APJ/SPHK1/NF-κB和APJ/PAI-1/TGFβ信号轴,并降低NF-κB p65和SMAD2的磷酸化水平以及该轴下游细胞因子和ECM的表达。最后,6 种 SphK1 抑制剂(芍药苷、黄芪苷、大黄素、甘草次黄酮、槲皮素和桔梗苷)和 3 种 PAI-1 抑制剂(甘草次黄酮、甘草查耳酮 B 和异桔梗苷)被鉴定为 HBF 中的潜在活性成分:简而言之,我们的研究强调了 HBF 在 DOX 诱导的 AKI 模型小鼠中的肾保护作用,通过不同的病理过程阐明了其机制,并确定了关键的生物活性化合物。这些发现为拓宽 HBF 的临床应用和揭示其分子作用模式提供了新的视角。
{"title":"Protective effect of Huashi Baidu formula against AKI and active ingredients that target SphK1 and PAI-1.","authors":"Yute Zhong, Xia Du, Ping Wang, Weijie Li, Cong Xia, Dan Wu, Hong Jiang, Haiyu Xu, Luqi Huang","doi":"10.1186/s13020-024-01024-7","DOIUrl":"10.1186/s13020-024-01024-7","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Huashi Baidu Formula (HBF) is a clinical formula known for its efficacy against coronavirus disease 2019 (COVID-19). HBF may reduce the number of patients with abnormal serum creatinine while improving respiratory symptoms, suggesting that this formula may have potential for treating acute kidney injury (AKI). However, the protective effect of HBF on AKI has not been definitively confirmed, and the mechanism remains unclear. Therefore, the present study explored the renoprotective effects and molecular mechanisms of HBF and screened for its active ingredients to identify new potential applications of renoprotection by HBF.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The present study first assessed the protective effects of HBF on AKI in a DOX-induced mouse model. Then, RNA-seq and bioinformatics analyses were used to explore the related pathological processes and potential molecular mechanisms, which were subsequently validated using qRT-PCR and Western blotting. Furthermore, candidate compounds with potential binding affinity to two pivotal targets, sphingosine kinase 1 (SphK1) and plasminogen activator inhibitor-1 (PAI-1), were screened from the 29 constituents present in the blood using Microscale Thermophoresis (MST). Finally, to identify the active ingredients, the candidate components were re-screened using the SphK1 kinase activity detection system or the uPA/PAI-1 substrate colorimetric assay system.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In the DOX-induced AKI mouse model, therapeutic administration of HBF significantly reduced the levels of CRE, BUN, TNF-α, IL-1β, IL-6, and UA in plasma and the levels of MDA, T-CHO, and TG in kidney tissue. Additionally, the levels of TP and Alb in plasma and SOD and CAT in the kidney tissue were significantly increased. Histopathological assessment revealed that HBF reduced tubular vacuolation, renal interstitial inflammatory cell infiltration, tubular atrophy, and positive staining of renal interstitial collagen. RNA-seq and bioinformatics analyses showed that oxidative stress, the immune-inflammatory response, and extracellular matrix (ECM) formation could be the pathological processes that HBF targets to exerts its renoprotective effects. Furthermore, HBF regulated the APJ/SPHK1/NF-κB and APJ/PAI-1/TGFβ signaling axes and reduced the phosphorylation levels of NF-κB p65 and SMAD2 and the expression of cytokines and the ECM downstream of the axis. Finally, six SphK1 inhibitors (paeoniflorin, astragalin, emodin, glycyrrhisoflavone, quercetin, and liquiritigenin) and three PAI-1 inhibitors (glycyrrhisoflavone, licochalcone B, and isoliquiritigenin) were identified as potentially active ingredients in HBF.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;In brief, our investigation underscores the renoprotective effect of HBF in a DOX-induced AKI model mice, elucidating its mechanisms through distinct pathological processes and identifying key bioactive compounds. These findings offer new insights for br","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"19 1","pages":"152"},"PeriodicalIF":5.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11529477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142563988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Suppression of ferroptosis through the SLC7A11/glutathione/glutathione peroxidase 4 axis contributes to the therapeutic action of the Tangshenning formula on diabetic renal tubular injury. 通过 SLC7A11/谷胱甘肽/谷胱甘肽过氧化物酶 4 轴抑制铁变态反应是丹参宁方对糖尿病肾小管损伤的治疗作用之一。
IF 5.3 3区 医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-10-29 DOI: 10.1186/s13020-024-01007-8
Xiao-Meng Shan, Chun-Wei Chen, Da-Wei Zou, Yan-Bin Gao, Yin-Ying Ba, Jia-Xin He, Zhi-Yao Zhu, Jia-Jun Liang

Background: Tangshenning (TSN) is a safe and effective formula to treat diabetic nephropathy (DN), and clinical studies have demonstrated that its therapeutic effects are related to oxidative stress improvements in patients. Herein, this study aims to explore the potential mechanism of how TSN alleviates diabetic renal tubular injury.

Methods: The ultrahigh pressure liquid chromatography-quadrupole-time of flight mass spectrometry (UPLC-QTOF/MS) was used to identify the chemical composition and serum components of TSN. KK-Ay mice served to investigate the protective effects and regulatory mechanisms of TSN on tubular damage in DN. Furthermore, inhibitors and inducers of ferroptosis were employed in high glucose-cultured tubular epithelial cells (TECs) to verify the potential mechanisms of TSN. The expressions of proteins related to renal tubular injury, ferroptosis and solute carrier family 7, member 11 (SLC7A11)/glutathione (GSH)/glutathione peroxidase 4 (GPX4) axis were analyzed by western blot and immunofluorescence. Mitochondrial ultrastructure was observed in kidney tissues and TECs by a transmission electron microscope. Pathological changes in the renal tissues were observed by HE, PAS, and Prussian blue staining. Ferroptosis-related reactive oxygen species (ROS), malondialdehyde (MDA), ferrous ion, the intake of cystine, GSH, and oxidized glutathione (GSSG) were evaluated and contrasted in vivo or in vitro.

Results: 51 compounds of TSN powder and 11 components in TSN-containing serum were identified by UPLC-QTOF/MS method. Administration of TSN ameliorated the elevated levels of proteinuria, serum creatinine, blood urea nitrogen, abnormal expression of renal tubular injury markers, and pathological damage to the renal tubules in DN mice model. Intriguingly, a strong inhibition of ferroptosis after TSN treatment occurred in both DN mice model and high glucose-cultured TECs. Notably, induction of ferroptosis by erastin attenuated the protective effect of TSN in high glucose-cultured TECs, while the ferroptosis inhibition by ferrostatin-1 treatment protected renal tubular, which was similar to TSN, suggesting the contribution of TSN-mediated by the inhibition of ferroptosis in DN progression. Mechanistically, TSN upregulated the SLC7A11/GSH/GPX4 axis to inhibit ferroptosis.

Conclusion: TSN may delay the DN progression and attenuate the renal tubular injury by inhibiting the ferroptosis regulated by the SLC7A11/GSH/GPX4 axis.

背景:丹参宁(TSN)是治疗糖尿病肾病(DN)安全有效的方剂,临床研究表明其治疗效果与患者氧化应激的改善有关。在此,本研究旨在探讨 TSN 如何缓解糖尿病肾小管损伤的潜在机制:方法:采用超高压液相色谱-四极杆飞行时间质谱法(UPLC-QTOF/MS)鉴定 TSN 的化学成分和血清成分。KK-Ay 小鼠用于研究 TSN 对 DN 肾小管损伤的保护作用和调节机制。此外,还在高糖培养的肾小管上皮细胞(TECs)中使用了铁突变抑制剂和诱导剂,以验证 TSN 的潜在机制。通过 Western 印迹和免疫荧光分析了与肾小管损伤、铁突变和溶质运载家族 7 成员 11(SLC7A11)/谷胱甘肽(GSH)/谷胱甘肽过氧化物酶 4(GPX4)轴相关的蛋白质表达。透射电子显微镜观察了肾组织和TEC的线粒体超微结构。通过HE、PAS和普鲁士蓝染色观察了肾组织的病理变化。在体内或体外评估和对比了与铁变态反应相关的活性氧(ROS)、丙二醛(MDA)、亚铁离子、胱氨酸、GSH 和氧化谷胱甘肽(GSSG)的摄入量:UPLC-QTOF/MS方法鉴定了TSN粉末中的51种化合物和含TSN血清中的11种成分。服用TSN后,DN小鼠模型的蛋白尿、血清肌酐、血尿素氮水平升高,肾小管损伤标志物表达异常,肾小管病理损伤等症状得到改善。耐人寻味的是,TSN 处理后,DN 小鼠模型和高糖培养的 TECs 都出现了强烈的铁突变抑制。值得注意的是,麦拉宁诱导铁嗜酸化会减弱TSN对高糖培养的TECs的保护作用,而铁前列素-1抑制铁嗜酸化对肾小管的保护作用与TSN相似,这表明TSN通过抑制铁嗜酸化在DN进展中起了重要作用。从机制上讲,TSN上调了SLC7A11/GSH/GPX4轴以抑制铁氧化:结论:TSN可通过抑制由SLC7A11/GSH/GPX4轴调控的铁突变,延缓DN的进展并减轻肾小管损伤。
{"title":"Suppression of ferroptosis through the SLC7A11/glutathione/glutathione peroxidase 4 axis contributes to the therapeutic action of the Tangshenning formula on diabetic renal tubular injury.","authors":"Xiao-Meng Shan, Chun-Wei Chen, Da-Wei Zou, Yan-Bin Gao, Yin-Ying Ba, Jia-Xin He, Zhi-Yao Zhu, Jia-Jun Liang","doi":"10.1186/s13020-024-01007-8","DOIUrl":"10.1186/s13020-024-01007-8","url":null,"abstract":"<p><strong>Background: </strong>Tangshenning (TSN) is a safe and effective formula to treat diabetic nephropathy (DN), and clinical studies have demonstrated that its therapeutic effects are related to oxidative stress improvements in patients. Herein, this study aims to explore the potential mechanism of how TSN alleviates diabetic renal tubular injury.</p><p><strong>Methods: </strong>The ultrahigh pressure liquid chromatography-quadrupole-time of flight mass spectrometry (UPLC-QTOF/MS) was used to identify the chemical composition and serum components of TSN. KK-Ay mice served to investigate the protective effects and regulatory mechanisms of TSN on tubular damage in DN. Furthermore, inhibitors and inducers of ferroptosis were employed in high glucose-cultured tubular epithelial cells (TECs) to verify the potential mechanisms of TSN. The expressions of proteins related to renal tubular injury, ferroptosis and solute carrier family 7, member 11 (SLC7A11)/glutathione (GSH)/glutathione peroxidase 4 (GPX4) axis were analyzed by western blot and immunofluorescence. Mitochondrial ultrastructure was observed in kidney tissues and TECs by a transmission electron microscope. Pathological changes in the renal tissues were observed by HE, PAS, and Prussian blue staining. Ferroptosis-related reactive oxygen species (ROS), malondialdehyde (MDA), ferrous ion, the intake of cystine, GSH, and oxidized glutathione (GSSG) were evaluated and contrasted in vivo or in vitro.</p><p><strong>Results: </strong>51 compounds of TSN powder and 11 components in TSN-containing serum were identified by UPLC-QTOF/MS method. Administration of TSN ameliorated the elevated levels of proteinuria, serum creatinine, blood urea nitrogen, abnormal expression of renal tubular injury markers, and pathological damage to the renal tubules in DN mice model. Intriguingly, a strong inhibition of ferroptosis after TSN treatment occurred in both DN mice model and high glucose-cultured TECs. Notably, induction of ferroptosis by erastin attenuated the protective effect of TSN in high glucose-cultured TECs, while the ferroptosis inhibition by ferrostatin-1 treatment protected renal tubular, which was similar to TSN, suggesting the contribution of TSN-mediated by the inhibition of ferroptosis in DN progression. Mechanistically, TSN upregulated the SLC7A11/GSH/GPX4 axis to inhibit ferroptosis.</p><p><strong>Conclusion: </strong>TSN may delay the DN progression and attenuate the renal tubular injury by inhibiting the ferroptosis regulated by the SLC7A11/GSH/GPX4 axis.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"19 1","pages":"151"},"PeriodicalIF":5.3,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11523893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of Chinese herbal medicine in the regulation of oxidative stress in treating hypertension: from therapeutics to mechanisms. 中药在治疗高血压的氧化应激调节中的作用:从治疗到机制。
IF 5.3 3区 医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-10-29 DOI: 10.1186/s13020-024-01022-9
Zixuan Jin, Yu Lan, Junying Li, Pengqian Wang, Xingjiang Xiong

Background: Although the pathogenesis of essential hypertension is not clear, a large number of studies have shown that oxidative stress plays an important role in the occurrence and development of hypertension and target organ damage.

Purpose: This paper systematically summarizes the relationship between oxidative stress and hypertension, and explores the potential mechanisms of Chinese herbal medicine (CHM) in the regulation of oxidative stress in hypertension, aiming to establish a scientific basis for the treatment of hypertension with CHM.

Methods: To review the efficacy and mechanism by which CHM treat hypertension through targeting oxidative stress, data were searched from PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, the Chinese National Knowledge Infrastructure, the VIP Information Database, the Chinese Biomedical Literature Database, and the Wanfang Database from their inception up to January 2024. NPs were classified and summarized by their mechanisms of action.

Results: In hypertension, the oxidative stress pathway of the body is abnormally activated, and the antioxidant system is inhibited, leading to the imbalance between the oxidative and antioxidative capacity. Meanwhile, excessive production of reactive oxygen species can lead to endothelial damage and vascular dysfunction, resulting in inflammation and immune response, thereby promoting the development of hypertension and damaging the heart, brain, kidneys, blood vessels, and other target organs. Numerous studies suggested that inhibiting oxidative stress may be the potential therapeutic target for hypertension. In recent years, the clinical advantages of traditional Chinese medicine (TCM) in the treatment of hypertension have gradually attracted attention. TCM, including active ingredients of CHM, single Chinese herb, TCM classic formula and traditional Chinese patent medicine, can not only reduce blood pressure, improve clinical symptoms, but also improve oxidative stress, thus extensively affect vascular endothelium, renin-angiotensin-aldosterone system, sympathetic nervous system, target organ damage, as well as insulin resistance, hyperlipidemia, hyperhomocysteinemia and other pathological mechanisms and hypertension related risk factors.

Conclusions: CHM display a beneficial multi-target, multi-component, overall and comprehensive regulation characteristics, and have potential value for clinical application in the treatment of hypertension by regulating the level of oxidative stress.

背景:目的:本文系统总结了氧化应激与高血压的关系,探讨了中药调节高血压氧化应激的潜在机制,旨在为中药治疗高血压建立科学依据:为了回顾中药通过靶向氧化应激治疗高血压的疗效和机制,我们检索了PubMed、EMBASE、Cochrane Central Register of Controlled Trials、中国国家知识基础设施、VIP信息数据库、中国生物医学文献数据库和万方数据库从开始到2024年1月的数据。结果表明:在高血压患者中,氧化应激途径的作用是最重要的:结果:高血压患者体内氧化应激通路异常激活,抗氧化系统受到抑制,导致氧化能力和抗氧化能力失衡。同时,活性氧的过度产生会导致血管内皮损伤和血管功能障碍,引起炎症和免疫反应,从而促进高血压的发展,损害心、脑、肾、血管等靶器官。大量研究表明,抑制氧化应激可能是高血压的潜在治疗靶点。近年来,中药治疗高血压的临床优势逐渐受到关注。中药包括CHM的有效成分、单味中草药、中医经典方剂和中成药,不仅能降低血压、改善临床症状,还能改善氧化应激,从而广泛影响血管内皮、肾素-血管紧张素-醛固酮系统、交感神经系统、靶器官损害,以及胰岛素抵抗、高脂血症、高同型半胱氨酸血症等病理机制和高血压相关危险因素:CHM具有多靶点、多成分、整体和综合调控的特点,通过调节氧化应激水平治疗高血压具有潜在的临床应用价值。
{"title":"The role of Chinese herbal medicine in the regulation of oxidative stress in treating hypertension: from therapeutics to mechanisms.","authors":"Zixuan Jin, Yu Lan, Junying Li, Pengqian Wang, Xingjiang Xiong","doi":"10.1186/s13020-024-01022-9","DOIUrl":"10.1186/s13020-024-01022-9","url":null,"abstract":"<p><strong>Background: </strong>Although the pathogenesis of essential hypertension is not clear, a large number of studies have shown that oxidative stress plays an important role in the occurrence and development of hypertension and target organ damage.</p><p><strong>Purpose: </strong>This paper systematically summarizes the relationship between oxidative stress and hypertension, and explores the potential mechanisms of Chinese herbal medicine (CHM) in the regulation of oxidative stress in hypertension, aiming to establish a scientific basis for the treatment of hypertension with CHM.</p><p><strong>Methods: </strong>To review the efficacy and mechanism by which CHM treat hypertension through targeting oxidative stress, data were searched from PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, the Chinese National Knowledge Infrastructure, the VIP Information Database, the Chinese Biomedical Literature Database, and the Wanfang Database from their inception up to January 2024. NPs were classified and summarized by their mechanisms of action.</p><p><strong>Results: </strong>In hypertension, the oxidative stress pathway of the body is abnormally activated, and the antioxidant system is inhibited, leading to the imbalance between the oxidative and antioxidative capacity. Meanwhile, excessive production of reactive oxygen species can lead to endothelial damage and vascular dysfunction, resulting in inflammation and immune response, thereby promoting the development of hypertension and damaging the heart, brain, kidneys, blood vessels, and other target organs. Numerous studies suggested that inhibiting oxidative stress may be the potential therapeutic target for hypertension. In recent years, the clinical advantages of traditional Chinese medicine (TCM) in the treatment of hypertension have gradually attracted attention. TCM, including active ingredients of CHM, single Chinese herb, TCM classic formula and traditional Chinese patent medicine, can not only reduce blood pressure, improve clinical symptoms, but also improve oxidative stress, thus extensively affect vascular endothelium, renin-angiotensin-aldosterone system, sympathetic nervous system, target organ damage, as well as insulin resistance, hyperlipidemia, hyperhomocysteinemia and other pathological mechanisms and hypertension related risk factors.</p><p><strong>Conclusions: </strong>CHM display a beneficial multi-target, multi-component, overall and comprehensive regulation characteristics, and have potential value for clinical application in the treatment of hypertension by regulating the level of oxidative stress.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"19 1","pages":"150"},"PeriodicalIF":5.3,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic reprogramming and renal fibrosis: what role might Chinese medicine play? 代谢重编程与肾脏纤维化:中医药能发挥什么作用?
IF 5.3 3区 医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-10-28 DOI: 10.1186/s13020-024-01004-x
Weili Wang, Rong Dai, Meng Cheng, Yizhen Chen, Yilin Gao, Xin Hong, Wei Zhang, Yiping Wang, Lei Zhang

Metabolic reprogramming is a pivotal biological process in which cellular metabolic patterns change to meet the energy demands of increased cell growth and proliferation. In this review, we explore metabolic reprogramming and its impact on fibrotic diseases, providing a detailed overview of the key processes involved in the metabolic reprogramming of renal fibrosis, including fatty acid decomposition and synthesis, glycolysis, and amino acid catabolism. In addition, we report that Chinese medicine ameliorates renal inflammation, oxidative stress, and apoptosis in chronic kidney disease by regulating metabolic processes, thereby inhibiting renal fibrosis. Furthermore, we reveal that multiple targets and signaling pathways contribute to the metabolic regulatory effects of Chinese medicine. In summary, this review aims to elucidate the mechanisms by which Chinese medicine inhibits renal fibrosis through the remodeling of renal cell metabolic processes, with the goal of discovering new therapeutic drugs for treating renal fibrosis.

代谢重编程是一个关键的生物过程,在这一过程中,细胞代谢模式发生改变,以满足细胞生长和增殖增加对能量的需求。在这篇综述中,我们探讨了代谢重编程及其对纤维化疾病的影响,详细概述了参与肾纤维化代谢重编程的关键过程,包括脂肪酸分解和合成、糖酵解和氨基酸分解。此外,我们还报告了中药通过调节代谢过程改善慢性肾脏病的肾脏炎症、氧化应激和细胞凋亡,从而抑制肾脏纤维化。此外,我们还揭示了多种靶点和信号通路对中药代谢调节作用的贡献。综上所述,本综述旨在阐明中药通过重塑肾细胞代谢过程抑制肾纤维化的机制,以期发现治疗肾纤维化的新药。
{"title":"Metabolic reprogramming and renal fibrosis: what role might Chinese medicine play?","authors":"Weili Wang, Rong Dai, Meng Cheng, Yizhen Chen, Yilin Gao, Xin Hong, Wei Zhang, Yiping Wang, Lei Zhang","doi":"10.1186/s13020-024-01004-x","DOIUrl":"10.1186/s13020-024-01004-x","url":null,"abstract":"<p><p>Metabolic reprogramming is a pivotal biological process in which cellular metabolic patterns change to meet the energy demands of increased cell growth and proliferation. In this review, we explore metabolic reprogramming and its impact on fibrotic diseases, providing a detailed overview of the key processes involved in the metabolic reprogramming of renal fibrosis, including fatty acid decomposition and synthesis, glycolysis, and amino acid catabolism. In addition, we report that Chinese medicine ameliorates renal inflammation, oxidative stress, and apoptosis in chronic kidney disease by regulating metabolic processes, thereby inhibiting renal fibrosis. Furthermore, we reveal that multiple targets and signaling pathways contribute to the metabolic regulatory effects of Chinese medicine. In summary, this review aims to elucidate the mechanisms by which Chinese medicine inhibits renal fibrosis through the remodeling of renal cell metabolic processes, with the goal of discovering new therapeutic drugs for treating renal fibrosis.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"19 1","pages":"148"},"PeriodicalIF":5.3,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shen-Bai-Jie-Du decoction suppresses the progression of colorectal adenoma to carcinoma through regulating gut microbiota and short-chain fatty acids. 神白解毒汤通过调节肠道微生物群和短链脂肪酸抑制结直肠腺瘤向癌的发展。
IF 5.3 3区 医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-10-28 DOI: 10.1186/s13020-024-01019-4
Min Huang, Ye Zhang, Mingxin Ni, Meng Shen, Yuquan Tao, Weixing Shen, Dongdong Sun, Liu Li, Changliang Xu, Jiani Tan, Yueyang Lai, Chengtao Yu, Lihuiping Tao, Minmin Fan, Haibo Cheng

Background: Shen-Bai-Jie-Du decoction (SBJDD), a traditional Chinese herb formula developed based on evidence-based medicine, is efficacy to reduce the recurrence and carcinogenesis of colorectal adenoma. However, the mechanism of SBJDD to treat colorectal adenoma remains unclear. The present study aims to investigate the efficacy and mechanism of SBJDD on colorectal adenoma carcinogenesis from the aspects of regulating gut microbiota and short-chain fatty acids (SCFAs).

Methods: Twenty-one patients diagnosed with colorectal adenoma were recruited in the study and required to take SBJDD for four consecutive weeks. Analysis of gut microbiota was conducted using 16S rRNA gene amplicon sequencing, while levels of SCFAs in fecal and serum samples were determined through HPLC-MS/MS. Additionally, twenty-four Apcmin/+ mice were randomly assigned to normal diet (ND), high-fat diet (HFD), and SBJDD groups. The pharmacological effects and mechanism of SBJDD on colorectal adenoma carcinogenesis were assessed using RT-qPCR, HE staining, IHC staining, Western blot, IF staining, and Flow cytometry assays.

Results: Our clinical study has shown that SBJDD can regulate the gut microbiota composition and enhance SCFAs production in patients with colorectal adenoma. SBJDD alleviated colorectal adenoma formation and carcinogenesis, as well as protected the integrity of the intestinal barrier in the Apcmin/+ mice model compared to the HFD group. Additionally, SBJDD was found to regulate gut microbiota capable of producing SCFAs. G protein-coupled receptors GPR43, GPR41, and GPR109a were effectively activated in the SBJDD group, while HDAC1 and HDAC3 were inhibited. Furthermore, decreased expression levels of interleukin 1 beta (IL-1β) and interleukin 6 (IL-6), along with elevated expression level of interleukin 10 (IL-10), were observed in the colorectal tissue of the SBJDD group. Finally, SBJDD exhibited the ability to reduce the proportion of M1-type macrophages while increasing the proportion of M2-type macrophages.

Conclusions: Our study objectively demonstrated the pharmacological effects of SBJDD in inhibiting the progression of colorectal adenoma and investigated its mechanisms in terms of regulating gut microbiota, increasing SCFAs, and reducing colorectal inflammation.

背景神白解毒汤(SBJDD)是根据循证医学开发的传统中草药配方,具有减少大肠腺瘤复发和癌变的功效。然而,SBJDD 治疗大肠腺瘤的机制仍不清楚。本研究旨在从调节肠道微生物群和短链脂肪酸(SCFAs)方面探讨SBJDD对大肠腺瘤癌变的疗效和机制:研究招募了21名确诊为大肠腺瘤的患者,要求他们连续服用SBJDD四周。采用 16S rRNA 基因扩增序列分析肠道微生物群,并通过 HPLC-MS/MS 测定粪便和血清样本中的 SCFAs 含量。此外,24 只 Apcmin/+ 小鼠被随机分配到正常饮食组(ND)、高脂饮食组(HFD)和 SBJDD 组。采用 RT-qPCR、HE 染色、IHC 染色、Western 印迹、IF 染色和流式细胞术等方法评估了 SBJDD 对大肠腺癌发生的药理作用和机制:结果:我们的临床研究表明,SBJDD 可以调节结直肠腺瘤患者的肠道微生物群组成,促进 SCFAs 的产生。与高纤维食物组相比,SBJDD 可减轻 Apcmin/+ 小鼠模型中结直肠腺瘤的形成和癌变,并保护肠道屏障的完整性。此外,研究还发现 SBJDD 能够调节肠道微生物群,使其能够产生 SCFAs。在 SBJDD 组中,G 蛋白偶联受体 GPR43、GPR41 和 GPR109a 被有效激活,而 HDAC1 和 HDAC3 则受到抑制。此外,在 SBJDD 组的结直肠组织中观察到白细胞介素 1β(IL-1β)和白细胞介素 6(IL-6)的表达水平降低,白细胞介素 10(IL-10)的表达水平升高。最后,SBJDD 能降低 M1 型巨噬细胞的比例,同时增加 M2 型巨噬细胞的比例:我们的研究客观地证明了 SBJDD 在抑制结直肠腺瘤进展方面的药理作用,并从调节肠道微生物群、增加 SCFAs 和减少结直肠炎症等方面研究了其作用机制。
{"title":"Shen-Bai-Jie-Du decoction suppresses the progression of colorectal adenoma to carcinoma through regulating gut microbiota and short-chain fatty acids.","authors":"Min Huang, Ye Zhang, Mingxin Ni, Meng Shen, Yuquan Tao, Weixing Shen, Dongdong Sun, Liu Li, Changliang Xu, Jiani Tan, Yueyang Lai, Chengtao Yu, Lihuiping Tao, Minmin Fan, Haibo Cheng","doi":"10.1186/s13020-024-01019-4","DOIUrl":"10.1186/s13020-024-01019-4","url":null,"abstract":"<p><strong>Background: </strong>Shen-Bai-Jie-Du decoction (SBJDD), a traditional Chinese herb formula developed based on evidence-based medicine, is efficacy to reduce the recurrence and carcinogenesis of colorectal adenoma. However, the mechanism of SBJDD to treat colorectal adenoma remains unclear. The present study aims to investigate the efficacy and mechanism of SBJDD on colorectal adenoma carcinogenesis from the aspects of regulating gut microbiota and short-chain fatty acids (SCFAs).</p><p><strong>Methods: </strong>Twenty-one patients diagnosed with colorectal adenoma were recruited in the study and required to take SBJDD for four consecutive weeks. Analysis of gut microbiota was conducted using 16S rRNA gene amplicon sequencing, while levels of SCFAs in fecal and serum samples were determined through HPLC-MS/MS. Additionally, twenty-four Apc<sup>min/+</sup> mice were randomly assigned to normal diet (ND), high-fat diet (HFD), and SBJDD groups. The pharmacological effects and mechanism of SBJDD on colorectal adenoma carcinogenesis were assessed using RT-qPCR, HE staining, IHC staining, Western blot, IF staining, and Flow cytometry assays.</p><p><strong>Results: </strong>Our clinical study has shown that SBJDD can regulate the gut microbiota composition and enhance SCFAs production in patients with colorectal adenoma. SBJDD alleviated colorectal adenoma formation and carcinogenesis, as well as protected the integrity of the intestinal barrier in the Apc<sup>min/+</sup> mice model compared to the HFD group. Additionally, SBJDD was found to regulate gut microbiota capable of producing SCFAs. G protein-coupled receptors GPR43, GPR41, and GPR109a were effectively activated in the SBJDD group, while HDAC1 and HDAC3 were inhibited. Furthermore, decreased expression levels of interleukin 1 beta (IL-1β) and interleukin 6 (IL-6), along with elevated expression level of interleukin 10 (IL-10), were observed in the colorectal tissue of the SBJDD group. Finally, SBJDD exhibited the ability to reduce the proportion of M1-type macrophages while increasing the proportion of M2-type macrophages.</p><p><strong>Conclusions: </strong>Our study objectively demonstrated the pharmacological effects of SBJDD in inhibiting the progression of colorectal adenoma and investigated its mechanisms in terms of regulating gut microbiota, increasing SCFAs, and reducing colorectal inflammation.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"19 1","pages":"149"},"PeriodicalIF":5.3,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Total tanshinones ameliorates cGAS-STING-mediated inflammatory and autoimmune diseases by affecting STING-IRF3 binding. 更正:丹参酮总量通过影响 STING-IRF3 的结合,改善 cGAS-STING 介导的炎症和自身免疫性疾病。
IF 5.3 3区 医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-10-23 DOI: 10.1186/s13020-024-00996-w
Chengwei Li, Jincai Wen, Xiaoyan Zhan, Wei Shi, Xiu Ye, Qing Yao, Simin Chen, Congyang Zheng, Xianlin Wang, Xinru Wen, Xiaohe Xiao, Yinghao Wang, Zhaofang Bai
{"title":"Correction: Total tanshinones ameliorates cGAS-STING-mediated inflammatory and autoimmune diseases by affecting STING-IRF3 binding.","authors":"Chengwei Li, Jincai Wen, Xiaoyan Zhan, Wei Shi, Xiu Ye, Qing Yao, Simin Chen, Congyang Zheng, Xianlin Wang, Xinru Wen, Xiaohe Xiao, Yinghao Wang, Zhaofang Bai","doi":"10.1186/s13020-024-00996-w","DOIUrl":"10.1186/s13020-024-00996-w","url":null,"abstract":"","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"19 1","pages":"147"},"PeriodicalIF":5.3,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11515680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: The improvement of modified Si-Miao granule on hepatic insulin resistance and glycogen synthesis in type 2 diabetes mellitus involves the inhibition of TNF-α/JNK1/IRS-2 pathway: network pharmacology, molecular docking, and experimental validation. 更正:改良四妙颗粒对2型糖尿病患者肝脏胰岛素抵抗和糖原合成的改善涉及对TNF-α/JNK1/IRS-2通路的抑制:网络药理学、分子对接和实验验证。
IF 5.3 3区 医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-10-21 DOI: 10.1186/s13020-024-01012-x
Zebiao Cao, Xianzhe Wang, Zhili Zeng, Zhaojun Yang, Yuping Lin, Lu Sun, Qiyun Lu, Guanjie Fan
{"title":"Correction: The improvement of modified Si-Miao granule on hepatic insulin resistance and glycogen synthesis in type 2 diabetes mellitus involves the inhibition of TNF-α/JNK1/IRS-2 pathway: network pharmacology, molecular docking, and experimental validation.","authors":"Zebiao Cao, Xianzhe Wang, Zhili Zeng, Zhaojun Yang, Yuping Lin, Lu Sun, Qiyun Lu, Guanjie Fan","doi":"10.1186/s13020-024-01012-x","DOIUrl":"10.1186/s13020-024-01012-x","url":null,"abstract":"","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"19 1","pages":"146"},"PeriodicalIF":5.3,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zhi-Kang-Yin formula attenuates high-fat diet-induced metabolic disorders through modulating gut microbiota-bile acids axis in mice. 知康阴方通过调节小鼠肠道微生物群-胆汁酸轴减轻高脂饮食引起的代谢紊乱。
IF 5.3 3区 医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-10-18 DOI: 10.1186/s13020-024-01021-w
Yifan Li, Hao Wang, Xiaofang He, Weize Zhu, Yiyang Bao, Xinxin Gao, Wenjin Huang, Xinyu Ge, Wenjing Wei, Huan Zhang, Lili Sheng, Tao Zhang, Houkai Li

Background: Metabolic disorders have become one of the global medical problems. Due to the complexity of its pathogenesis, there is still no effective treatment. Bile acids (BAs) and gut microbiota (GM) have been proved to be closely related to host metabolism, which could be important targets for metabolic disorders. Zhi-Kang-Yin (ZKY) is a traditional Chinese medicine (TCM) formula developed by the research team according to theory of TCM and has been shown to improve metabolism in clinic. However, the underlying mechanisms are unclear.

Aim of the study: This study aimed to investigate the potential mechanisms of the beneficial effect of ZKY on metabolism.

Methods: High-fat diet (HFD)-fed mice were treated with and without ZKY. The glucose and lipid metabolism-related indexes were measured. BA profile, GM composition and hepatic transcriptome were then investigated to analyze the changes of BAs, GM, and hepatic gene expression. Moreover, the relationship between GM and BAs was identified with functional gene quantification and ex vivo fermentation experiment.

Results: ZKY reduced weight gain and lipid levels in both liver and serum, attenuated hepatic steatosis and improved glucose tolerance in HFD-fed mice. BA profile detection showed that ZKY changed the composition of BAs and increased the proportion of unconjugated BAs and non-12-OH BAs. Hepatic transcriptomic analysis revealed fatty acid metabolism and BA biosynthesis related pathways were regulated. In addition, ZKY significantly changed the structure of GM and upregulated the gene copy number of bacterial bile salt hydrolase. Meanwhile, ZKY directly promoted the growth of Bifidobacterium, which is a well-known bile salt hydrolase-producing genus. The ex vivo co-culture experiment with gut microbiota and BAs demonstrated that the changes of BAs profile in ZKY group were mediated by ZKY-shifted GM, which led to increased expression of genes associated with fatty acid degradation in the liver.

Conclusion: Our study indicated that the effect of ZKY on improving metabolism is associated with the modulation of GM-BAs axis, especially, by upregulating the abundance of bile salt hydrolase-expression bacteria and increasing the levels of unconjugated BAs. This study indicates that GM-BAs axis might be an important pathway for improving metabolic disorders by ZKY.

背景:代谢紊乱已成为全球医学难题之一。由于其发病机制的复杂性,目前仍没有有效的治疗方法。胆汁酸(BA)和肠道微生物群(GM)已被证实与宿主的新陈代谢密切相关,可能成为代谢紊乱的重要靶点。至康饮(ZKY)是研究团队根据中医理论研制的传统中药配方,在临床上已被证明能改善代谢。然而,其潜在机制尚不清楚:研究目的:本研究旨在探讨 ZKY 对代谢有益作用的潜在机制。测量葡萄糖和脂质代谢相关指标。然后研究 BA、GM 组成和肝脏转录组,分析 BA、GM 和肝脏基因表达的变化。此外,还通过功能基因定量和体内外发酵实验确定了 GM 与 BA 之间的关系:结果:ZKY 降低了高密度脂蛋白喂养小鼠的体重增加和肝脏及血清中的脂质水平,减轻了肝脏脂肪变性,改善了葡萄糖耐量。BA谱检测显示,ZKY改变了BA的组成,增加了非结合BA和非12-OH BA的比例。肝脏转录组分析显示,脂肪酸代谢和 BA 生物合成相关途径受到调控。此外,ZKY 还明显改变了 GM 的结构,并上调了细菌胆盐水解酶的基因拷贝数。同时,ZKY 直接促进了双歧杆菌的生长,而双歧杆菌是一种著名的产胆盐水解酶的菌属。肠道微生物群和胆盐水解酶的体外共培养实验表明,ZKY 组胆盐水解酶谱的变化是由 ZKY 转移的 GM 介导的,这导致肝脏中脂肪酸降解相关基因的表达增加:我们的研究表明,ZKY 对改善代谢的影响与 GM-BAs 轴的调节有关,特别是通过上调胆盐水解酶表达菌的丰度和增加非结合型 BAs 的水平。这项研究表明,GM-BAs 轴可能是 ZKY 改善代谢紊乱的一个重要途径。
{"title":"Zhi-Kang-Yin formula attenuates high-fat diet-induced metabolic disorders through modulating gut microbiota-bile acids axis in mice.","authors":"Yifan Li, Hao Wang, Xiaofang He, Weize Zhu, Yiyang Bao, Xinxin Gao, Wenjin Huang, Xinyu Ge, Wenjing Wei, Huan Zhang, Lili Sheng, Tao Zhang, Houkai Li","doi":"10.1186/s13020-024-01021-w","DOIUrl":"https://doi.org/10.1186/s13020-024-01021-w","url":null,"abstract":"<p><strong>Background: </strong>Metabolic disorders have become one of the global medical problems. Due to the complexity of its pathogenesis, there is still no effective treatment. Bile acids (BAs) and gut microbiota (GM) have been proved to be closely related to host metabolism, which could be important targets for metabolic disorders. Zhi-Kang-Yin (ZKY) is a traditional Chinese medicine (TCM) formula developed by the research team according to theory of TCM and has been shown to improve metabolism in clinic. However, the underlying mechanisms are unclear.</p><p><strong>Aim of the study: </strong>This study aimed to investigate the potential mechanisms of the beneficial effect of ZKY on metabolism.</p><p><strong>Methods: </strong>High-fat diet (HFD)-fed mice were treated with and without ZKY. The glucose and lipid metabolism-related indexes were measured. BA profile, GM composition and hepatic transcriptome were then investigated to analyze the changes of BAs, GM, and hepatic gene expression. Moreover, the relationship between GM and BAs was identified with functional gene quantification and ex vivo fermentation experiment.</p><p><strong>Results: </strong>ZKY reduced weight gain and lipid levels in both liver and serum, attenuated hepatic steatosis and improved glucose tolerance in HFD-fed mice. BA profile detection showed that ZKY changed the composition of BAs and increased the proportion of unconjugated BAs and non-12-OH BAs. Hepatic transcriptomic analysis revealed fatty acid metabolism and BA biosynthesis related pathways were regulated. In addition, ZKY significantly changed the structure of GM and upregulated the gene copy number of bacterial bile salt hydrolase. Meanwhile, ZKY directly promoted the growth of Bifidobacterium, which is a well-known bile salt hydrolase-producing genus. The ex vivo co-culture experiment with gut microbiota and BAs demonstrated that the changes of BAs profile in ZKY group were mediated by ZKY-shifted GM, which led to increased expression of genes associated with fatty acid degradation in the liver.</p><p><strong>Conclusion: </strong>Our study indicated that the effect of ZKY on improving metabolism is associated with the modulation of GM-BAs axis, especially, by upregulating the abundance of bile salt hydrolase-expression bacteria and increasing the levels of unconjugated BAs. This study indicates that GM-BAs axis might be an important pathway for improving metabolic disorders by ZKY.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"19 1","pages":"145"},"PeriodicalIF":5.3,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11490013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PrescDRL: deep reinforcement learning for herbal prescription planning in treatment of chronic diseases. PrescDRL:用于慢性病治疗中草药处方规划的深度强化学习。
IF 5.3 3区 医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-10-16 DOI: 10.1186/s13020-024-01005-w
Kuo Yang, Zecong Yu, Xin Su, Fengjin Zhang, Xiong He, Ning Wang, Qiguang Zheng, Feidie Yu, Tiancai Wen, Xuezhong Zhou

Treatment planning for chronic diseases is a critical task in medical artificial intelligence, particularly in traditional Chinese medicine (TCM). However, generating optimized sequential treatment strategies for patients with chronic diseases in different clinical encounters remains a challenging issue that requires further exploration. In this study, we proposed a TCM herbal prescription planning framework based on deep reinforcement learning for chronic disease treatment (PrescDRL). PrescDRL is a sequential herbal prescription optimization model that focuses on long-term effectiveness rather than achieving maximum reward at every step, thereby ensuring better patient outcomes. We constructed a high-quality benchmark dataset for sequential diagnosis and treatment of diabetes and evaluated PrescDRL against this benchmark. Our results showed that PrescDRL achieved a higher curative effect, with the single-step reward improving by 117% and 153% compared to doctors. Furthermore, PrescDRL outperformed the benchmark in prescription prediction, with precision improving by 40.5% and recall improving by 63%. Overall, our study demonstrates the potential of using artificial intelligence to improve clinical intelligent diagnosis and treatment in TCM.

慢性病的治疗规划是医学人工智能的一项重要任务,尤其是在传统中医领域。然而,为不同临床情况下的慢性病患者生成优化的序贯治疗策略仍是一个具有挑战性的问题,需要进一步探索。在这项研究中,我们提出了一个基于深度强化学习的慢性病治疗中药处方规划框架(PrescDRL)。PrescDRL 是一种顺序中药处方优化模型,它关注长期疗效,而不是在每一步都获得最大回报,从而确保患者获得更好的治疗效果。我们构建了一个高质量的糖尿病序贯诊断和治疗基准数据集,并根据该基准对 PrescDRL 进行了评估。结果表明,PrescDRL 取得了更高的疗效,与医生相比,单步奖励分别提高了 117% 和 153%。此外,PrescDRL 在处方预测方面的表现优于基准,精确度提高了 40.5%,召回率提高了 63%。总之,我们的研究证明了利用人工智能改善中医临床智能诊断和治疗的潜力。
{"title":"PrescDRL: deep reinforcement learning for herbal prescription planning in treatment of chronic diseases.","authors":"Kuo Yang, Zecong Yu, Xin Su, Fengjin Zhang, Xiong He, Ning Wang, Qiguang Zheng, Feidie Yu, Tiancai Wen, Xuezhong Zhou","doi":"10.1186/s13020-024-01005-w","DOIUrl":"https://doi.org/10.1186/s13020-024-01005-w","url":null,"abstract":"<p><p>Treatment planning for chronic diseases is a critical task in medical artificial intelligence, particularly in traditional Chinese medicine (TCM). However, generating optimized sequential treatment strategies for patients with chronic diseases in different clinical encounters remains a challenging issue that requires further exploration. In this study, we proposed a TCM herbal prescription planning framework based on deep reinforcement learning for chronic disease treatment (PrescDRL). PrescDRL is a sequential herbal prescription optimization model that focuses on long-term effectiveness rather than achieving maximum reward at every step, thereby ensuring better patient outcomes. We constructed a high-quality benchmark dataset for sequential diagnosis and treatment of diabetes and evaluated PrescDRL against this benchmark. Our results showed that PrescDRL achieved a higher curative effect, with the single-step reward improving by 117% and 153% compared to doctors. Furthermore, PrescDRL outperformed the benchmark in prescription prediction, with precision improving by 40.5% and recall improving by 63%. Overall, our study demonstrates the potential of using artificial intelligence to improve clinical intelligent diagnosis and treatment in TCM.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"19 1","pages":"144"},"PeriodicalIF":5.3,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11481742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Yiqihuoxue decoction (GSC) inhibits mitochondrial fission through the AMPK pathway to ameliorate EPCs senescence and optimize vascular aging transplantation regimens. 益气活血汤(GSC)通过AMPK途径抑制线粒体分裂,从而改善EPCs衰老,优化血管衰老移植方案。
IF 5.3 3区 医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-10-14 DOI: 10.1186/s13020-024-01008-7
Yinan Liu, Zenghui Niu, Xue Wang, Chengkui Xiu, Yanhong Hu, Jiali Wang, Yan Lei, Jing Yang

Background: During the aging process, the number and functional activity of endothelial progenitor cells (EPCs) are impaired, leading to the unsatisfactory efficacy of transplantation. Previous studies demonstrated that Yiqihuoxue decoction (Ginseng-Sanqi-Chuanxiong, GSC) exerts anti-vascular aging effects. The purpose of this study is to evaluated the effects of GSC on D-galactose (D-gal)induced senescence and the underlying mechanisms.

Methods: The levels of cellular senescence-related markers P16, P21, P53, AMPK and p-AMPK were detected by Western blot analysis (WB). SA-β-gal staining was used to evaluate cell senescence. EPCs function was measured by CCK-8, Transwell cell migration and cell adhesion assay. The morphological changes of mitochondria were detected by confocal microscopy. The protein and mRNA expression of mitochondrial fusion fission Drp1, Mff, Fis1, Mfn1, Mfn2 and Opa1 in mitochondria were detect using WB and RT-qPCR. Mitochondrial membrane potential, mtROS and ATP of EPCs were measured using IF. H&E staining was used to observe the pathological changes and IMT of the aorta. The expressions of AGEs, MMP-2 and VEGF in aorta were measured using Immunohistochemical (IHC). The levels of SOD, MDA, NO and ET-1 in serum were detected by SOD, MDA and NO kits.

Results: In vitro, GSC ameliorated the senescence of EPCs induced by D-gal and reduced the expression of P16, P21 and P53. The mitochondrial morphology of EPCs was restored, the expression of mitochondrial Drp1, Mff and Fis1 protein was decreased, the levels of mtROS and ATP were decreased, and mitochondrial function was improved. Meanwhile, the expression of AMPK and p-AMPK increased. The improvement effects of GSC on aging and mitochondrial morphology and function were were hindered after adding AMPK inhibitor. In vivo, GSC improved EPCs efficiency, ameliorated aortic structural disorder and decreased IMT in aging mice. The serum SOD level increased and MDA level decreased, indicating the improvement of antioxidant capacity. Increased NO content and ET-1 content suggested improvement of vascular endothelial function. The changes observed in SOD and MMP-2 suggested a reduction in vascular stiffness and the degree of vascular damage. The decreased expression of P21 and P53 indicates the delay of vascular senescence.

背景:在衰老过程中,内皮祖细胞(EPCs)的数量和功能活性会受损,导致移植效果不理想。以往的研究表明,益气补血汤(人参-三七-川芎汤)具有抗血管衰老的作用。本研究旨在评估人参三七川芎汤对D-半乳糖(D-gal)诱导的衰老的影响及其内在机制:方法:细胞衰老相关标志物 P16、P21、P53、AMPK 和 p-AMPK 的水平通过 Western 印迹分析(WB)进行检测。SA-β-gal染色用于评估细胞衰老。EPCs功能通过CCK-8、Transwell细胞迁移和细胞粘附试验进行检测。共聚焦显微镜检测线粒体的形态变化。利用 WB 和 RT-qPCR 检测线粒体中线粒体融合裂变 Drp1、Mff、Fis1、Mfn1、Mfn2 和 Opa1 的蛋白和 mRNA 表达。使用 IF 检测 EPCs 的线粒体膜电位、mtROS 和 ATP。用 H&E 染色观察主动脉的病理变化和内径。用免疫组化(IHC)方法检测主动脉中 AGEs、MMP-2 和 VEGF 的表达。用 SOD、MDA 和 NO 试剂盒检测血清中 SOD、MDA、NO 和 ET-1 的水平:结果:在体外,GSC能改善D-gal诱导的EPCs衰老,并减少P16、P21和P53的表达。EPCs 的线粒体形态得到恢复,线粒体 Drp1、Mff 和 Fis1 蛋白表达减少,mtROS 和 ATP 水平下降,线粒体功能得到改善。同时,AMPK 和 p-AMPK 的表达增加。加入 AMPK 抑制剂后,GSC 对衰老和线粒体形态及功能的改善作用受到阻碍。在体内,GSC 提高了 EPCs 的效率,改善了衰老小鼠的主动脉结构紊乱并降低了 IMT。血清 SOD 水平升高,MDA 水平降低,表明抗氧化能力提高。NO含量和ET-1含量的增加表明血管内皮功能得到改善。观察到的 SOD 和 MMP-2 的变化表明血管僵硬度和血管损伤程度有所降低。P21 和 P53 表达的减少表明血管衰老的延迟。
{"title":"Yiqihuoxue decoction (GSC) inhibits mitochondrial fission through the AMPK pathway to ameliorate EPCs senescence and optimize vascular aging transplantation regimens.","authors":"Yinan Liu, Zenghui Niu, Xue Wang, Chengkui Xiu, Yanhong Hu, Jiali Wang, Yan Lei, Jing Yang","doi":"10.1186/s13020-024-01008-7","DOIUrl":"https://doi.org/10.1186/s13020-024-01008-7","url":null,"abstract":"<p><strong>Background: </strong>During the aging process, the number and functional activity of endothelial progenitor cells (EPCs) are impaired, leading to the unsatisfactory efficacy of transplantation. Previous studies demonstrated that Yiqihuoxue decoction (Ginseng-Sanqi-Chuanxiong, GSC) exerts anti-vascular aging effects. The purpose of this study is to evaluated the effects of GSC on D-galactose (D-gal)induced senescence and the underlying mechanisms.</p><p><strong>Methods: </strong>The levels of cellular senescence-related markers P16, P21, P53, AMPK and p-AMPK were detected by Western blot analysis (WB). SA-β-gal staining was used to evaluate cell senescence. EPCs function was measured by CCK-8, Transwell cell migration and cell adhesion assay. The morphological changes of mitochondria were detected by confocal microscopy. The protein and mRNA expression of mitochondrial fusion fission Drp1, Mff, Fis1, Mfn1, Mfn2 and Opa1 in mitochondria were detect using WB and RT-qPCR. Mitochondrial membrane potential, mtROS and ATP of EPCs were measured using IF. H&E staining was used to observe the pathological changes and IMT of the aorta. The expressions of AGEs, MMP-2 and VEGF in aorta were measured using Immunohistochemical (IHC). The levels of SOD, MDA, NO and ET-1 in serum were detected by SOD, MDA and NO kits.</p><p><strong>Results: </strong>In vitro, GSC ameliorated the senescence of EPCs induced by D-gal and reduced the expression of P16, P21 and P53. The mitochondrial morphology of EPCs was restored, the expression of mitochondrial Drp1, Mff and Fis1 protein was decreased, the levels of mtROS and ATP were decreased, and mitochondrial function was improved. Meanwhile, the expression of AMPK and p-AMPK increased. The improvement effects of GSC on aging and mitochondrial morphology and function were were hindered after adding AMPK inhibitor. In vivo, GSC improved EPCs efficiency, ameliorated aortic structural disorder and decreased IMT in aging mice. The serum SOD level increased and MDA level decreased, indicating the improvement of antioxidant capacity. Increased NO content and ET-1 content suggested improvement of vascular endothelial function. The changes observed in SOD and MMP-2 suggested a reduction in vascular stiffness and the degree of vascular damage. The decreased expression of P21 and P53 indicates the delay of vascular senescence.</p>","PeriodicalId":10266,"journal":{"name":"Chinese Medicine","volume":"19 1","pages":"143"},"PeriodicalIF":5.3,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Chinese Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1